Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 11—November 2011

CME ACTIVITY - Research

Global Distribution and Epidemiologic Associations of Escherichia coli Clonal Group A, 1998–2007

James R. JohnsonComments to Author , Megan E. Menard, Tsai-Ling Lauderdale, Chris Kosmidis, David Gordon, Peter Collignon, Joel N. Maslow, Arjana Tambić Andrašević, and Michael A. Kuskowski
Author affiliations: Veterans Affairs Medical Center, Minneapolis, Minnesota, USA (J.R. Johnson, M.E. Menard, M.A. Kuskowski); University of Minnesota, Minneapolis (J.R. Johnson, M.A. Kuskowski); National Health Research Institutes, Zhunan, Taiwan (T.-L. Lauderdale); University of Athens Medical School, Athens, Greece (C. Kosmidis); Australian National University, Canberra, Australian Capital Territory, Australia (D. Gordon, P. Collignon); Canberra Hospital, Canberra (P. Collignon); Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA (J.N. Maslow); University of Pennsylvania, Philadelphia (J.N. Maslow); University Hospital for Infectious Diseases, Zagreb, Croatia (A. Tambić Andrašević)

Main Article

Table 4

Prevalence of clonal group A, by clinical/host variables, among 2,210 extraintestinal Escherichia coli isolates from 32 globally distributed centers, 1998–2007*

Clinical/host variable and year isolate obtained from patient clinical specimen No. clonal group A isolates/total no. isolates (%)† p value‡
Total TMP/SMZ susceptible TMP/SMZ resistant
Specimen type
Nonurine 48/653 (7.4) 9/318 (2.8) 39/335 (11.6) <0.001
Urine 88/1,470 (6.0) 21/739 (2.8) 67/731 (9.2) <0.001
Host age group, y
<18 16/250 (6.4) 4/118 (3.4) 12/132 (9.1) 0.08
>18 122/1,909 (6.4) 25/938 (2.7) 97/971 (10.0) <0.001
Host hospital status
Outpatient 84/1,135 (7.4) 17/573 (3.0) 67/562 (11.9) <0.001
Inpatient 54/926 (5.8) 13/434 (3.0) 41/488 (8.4) <0.001
Year isolated
1998–2002 95/1,330 (7.1) 21/661 (3.2) 74/669 (11.1) <0.001
2003–2007 49/880 (5.6) 9/422 (2.1) 40/458 (8.7) <0.001

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†Data for each clinical variable include only isolates for which status with respect to the particular variable was known.
‡p values, by Fisher exact test, for comparisons of TMP/SMZ-susceptible vs. -resistant isolates within each subgroup. For all comparisons between subgroups within a given category (whether overall or by TMP/SMZ phenotype), p>0.10.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†Data for each clinical variable include only isolates for which status with respect to the particular variable was known.
‡p values, by Fisher exact test, for comparisons of TMP/SMZ-susceptible vs. -resistant isolates within each subgroup. For all comparisons between subgroups within a given category (whether overall or by TMP/SMZ phenotype), p>0.10.

*TMP/SMZ, trimethoprim/sulfamethoxazole.
†Data for each clinical variable include only isolates for which status with respect to the particular variable was known.
‡p values, by Fisher exact test, for comparisons of TMP/SMZ-susceptible vs. -resistant isolates within each subgroup. For all comparisons between subgroups within a given category (whether overall or by TMP/SMZ phenotype), p>0.10.

Main Article

1Investigators who contributed data are listed at the end of this article.

TOP